Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(1.93)
# 3,012
Out of 4,855 analysts
48
Total ratings
28.85%
Success rate
-2.27%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIST Milestone Pharmaceuticals | Assumes: Buy | $5 | $1.73 | +189.02% | 2 | Jun 5, 2025 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $9 | $1.41 | +538.30% | 1 | Jun 2, 2025 | |
| PYPD PolyPid | Assumes: Buy | $11 | $3.27 | +236.39% | 2 | Jun 2, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $21 | $7.06 | +197.45% | 2 | May 28, 2025 | |
| RMTI Rockwell Medical | Initiates: Buy | $5 | $1.02 | +390.20% | 1 | Nov 14, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $3.83 | +213.32% | 1 | Nov 14, 2024 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $9 | $3.94 | +128.43% | 1 | Nov 14, 2024 | |
| OMER Omeros | Initiates: Buy | $9 | $3.77 | +138.73% | 2 | Nov 14, 2024 | |
| ADIL Adial Pharmaceuticals | Initiates: Buy | $8 | $0.57 | +1,298.85% | 1 | Nov 14, 2024 | |
| EBS Emergent BioSolutions | Reiterates: Buy | $16 | $6.63 | +141.33% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $13.98 | -7.01% | 1 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.38 | +82.65% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.10 | +233.33% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.56 | +1,685.71% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $6.31 | +7,110.78% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $29.49 | +100.07% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $111.13 | +61.97% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.62 | +3,459.87% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $7.51 | +19.92% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $31.71 | +0.91% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.99 | +1,105,427.64% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $30.22 | -27.20% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 → $40 | $61.93 | -35.41% | 3 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $17.03 | +193.60% | 1 | Jul 12, 2018 | |
Milestone Pharmaceuticals
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $1.73
Upside: +189.02%
Cardiol Therapeutics
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $1.41
Upside: +538.30%
PolyPid
Jun 2, 2025
Assumes: Buy
Price Target: $11
Current: $3.27
Upside: +236.39%
Trevi Therapeutics
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $7.06
Upside: +197.45%
Rockwell Medical
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.02
Upside: +390.20%
Achieve Life Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $3.83
Upside: +213.32%
Eupraxia Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.94
Upside: +128.43%
Omeros
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.77
Upside: +138.73%
Adial Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.57
Upside: +1,298.85%
Emergent BioSolutions
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $6.63
Upside: +141.33%
Aug 26, 2024
Initiates: Buy
Price Target: $13
Current: $13.98
Upside: -7.01%
Jun 13, 2024
Initiates: Buy
Price Target: $8
Current: $4.38
Upside: +82.65%
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $2.10
Upside: +233.33%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $0.56
Upside: +1,685.71%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $6.31
Upside: +7,110.78%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $29.49
Upside: +100.07%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $111.13
Upside: +61.97%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.62
Upside: +3,459.87%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $7.51
Upside: +19.92%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $31.71
Upside: +0.91%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.99
Upside: +1,105,427.64%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $30.22
Upside: -27.20%
May 7, 2020
Downgrades: Neutral
Price Target: $78 → $40
Current: $61.93
Upside: -35.41%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $17.03
Upside: +193.60%